alexa
Reach Us +44-1904-929220
All about Mycobacterium simiae in Brief | OMICS International
ISSN: 2161-0703
Journal of Medical Microbiology & Diagnosis

Like us on:

Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

All about Mycobacterium simiae in Brief

Mouhamad Nasser*

American University of Beirut- Medical Center, Lebanon

*Corresponding Author:
Mouhamad Nasser
Pulmonary/Critical Care Medicine
and American University of Beirut- Medical Center
Lebanon
Tel: 961-1-350000
E-mail: [email protected]

Received date: October 27, 2014; Accepted date: December 27, 2014; Published date: December 29, 2014

Citation: Nasser M (2014) All about Mycobacterium simiae in Brief. J Med Microb Diagn 4:175. doi:10.4172/2161-0703.1000175

Copyright: © 2014 Nasser M. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Medical Microbiology & Diagnosis

Abstract

More than hundreds pathogens of mycobacterium have been identified till now but a minority of these bugs cause diseases in humans. M. simiae, an emerging bacterium that has been discovered recently, commonly recovered from human sputum especially in patients with underlying lung diseases. Most commonly this bacterium is a bystander rather than a true culprit. Such differentiation is critical to avoid unnecessary long term treatment not free of side effects.

Keywords

Non-tuberculous mycobacterium; M. simiae; Immunocompetent; Lung diseases

Introduction

Different terms are used to define non-tuberculosis mycobacteria [NTM] including atypical mycobarcteria and mycobacteria other than tuberculosis [MOTT]. However, NTM terminology is the most used name worldwide. NTM, an emerging entity, includes more than 100 species with variable microbiological features, clinical manifestations and significances. Nevertheless, NTM therapy also differs between species.

NTMs are rods shaped bacilli similar to mycobacterium tuberculosis [MTB]. In 1959, Runyon classified these bacteria into four groups according to their ability to form pigment after exposure to light or dark and the rapidity of their growth as well (Table 1) [1].

Produce yellow pigment in light Slowly growing Runyon I
Yellow pigment in light and dark Slowly growing Runyon II
No pigment Slowly growing Runyon III
No pigment Rapidly growing Runyon IV

Table 1: NTM Runyon Classification

The majority of human pathogens are slowly grower like M. kansasi, M. marinum, M. avium, M. intracellular, M. simiae [1]. However, M. simiae is the only niacin-positive MOTT, which makes it easily confused with mycobacterium tuberculosis [2]. M. simiae like other NTM is a ubiquitous organism with huge environmental reservoirs, such as natural and municipal water, soil, aerosols, protozoan, animals, and humans [3].

In 1965, M. simiae was initially isolated from maccacus rhesus monkeys [4]. It was first reported in Israel, Cuba, and south western America and then reports from middle east and Asia identified the presence of this emerging specie [2,5].

Epidemiology

The incidence of diseases attributed to NTM is not well established, due to underreporting of new cases. On the other hand, the frequency of respiratory NTM is increasing worldwide. Data from Australia showed higher incidence in 2005 compared to 1999 [6,7].

Clinical manifestation

NTM have a broad spectrum of clinical manifestations. They can cause either symptomatic or asymptomatic infections. Four clinical syndromes account for nearly all cases: pulmonary diseases, lymphadenitis, skin or soft tissue diseases, and disseminated diseases especially in AIDS patients. All four clinical syndromes are increasing in frequency, particularly in immunosuppressed hosts [4]. Rarely M. simiae can be a cause of central line related blood stream infection especially in immunosuppressed patients [8]. M. simiae is commonly isolated from respiratory specimen without being considered as a true pathogen especially in immunocompetent patients [9,10].

Pulmonary symptoms due to M. simiae are nonspecific. Infected patients frequently present with cough, sputum production, hemoptysis, sweating, weight loss, low grade fever, and dyspnea [4,11]. Patients with underlying lung diseases such as prior pulmonary tuberculosis or silicosis, chronic obstructive pulmonary disease [COPD], and noncystic fibrosis bronchiectasis have higher risk for M. simiae than healthy people [11].The association between M. simiae and cystic fibrosis was also been described [12]. Furthermore, other co-morbidities, such as Diabetes Mellitus, cardiovascular diseases, and malignancies could also predispose to M. simiae infection [13]. Other than that, M. simiae can cause disseminated disease in immunocompromised patients mainly HIV [14]. For long time this organism was thought to cause disseminated infections only in immunocompromised individuals. However, recent reports showed that disseminated M. simiae can also be seen in immunocompetent patients [10]. M. simiae may rarely be a cause hematogenous spread from pneumonia, leading to multifocal osteomyelitis in immunocompetent patient [15].

Diagnosis

Differentiation between true M. simiae infection and colonization is critical since treatment of infected cases is recommended for at least one year after negative culture. Thus, the American Thoracic Society (ATS) and Infectious Disease Society of America (IDSA) developed guidelines criteria to diagnose NTM pulmonary diseases (Table 2).

Pulmonary symptoms + Radiographic findings that include:
-Nodular or cavitary opacities on chest radiograph.
OR
- Multifocal bronchiectasis with multiple small nodules on HRCT chest.
AND
Appropriate exclusion of other diagnoses.
Clinical
and Radiographic features
-Positive results of culture from at least two separate sputum specimen.
OR
-Positive result of culture from at least one bronchial wash or lavage.
- Mycobacterial histopathologic features (granulomatous inflammation or AFB) from transbronchial or other lung biopsy and positive culture for NTM.
OR
-Mycobacterial histopathologic features (granulomatous inflammation or AFB) on Biopsy and one or more positive sputum or bronchial washings for NTM.
Microbiologic

Table 2: ATS/ERS criteria for pulmonary NTM diagnosis

In addition to microbiologic information, these criteria include data about host factors, clinical, and radiological findings consistent with pulmonary diseases which mainly focused on recurrent isolation of mycobacteria from sputum or isolated from at least one bronchial wash in symptomatic patients [16]. Tuberculin skin test (TST) is not a specific test as positive results are seen in different types of mycobacterium. TST is positive in 76.9 % of M. simiae pulmonary cases [4].

Radiographic findings

Radiographic findings with NTM pulmonary infections could be very similar to those seen in MTB findings. In addition, most patients with NTM have structural lung diseases. Typical radiographic features include nodular lesions (100%), cavitary lesions (88.5%), and bronchiectasis (84.6%).The middle and lower lobes are commonly involved in M. simiae infections [4].

Treatment

Although NTM might share similar clinical and radiological findings, treatment approach is different between species. Therefore identification of mycobacterium species is extremely important whenever NTM is recovered. The choice of antibiotics depends on the susceptibility pattern obtained from in vitro susceptibility tests that includes Clinical and Laboratory Standards Institute (CLSI) E-test, agarbased testing methods, and the disk elution and diffusion method [17].

M. simiae isolates are susceptible to fluoroquinolones and amikacin but resistant to all others including isoniazid, capreomycin, minocycline, doxycycline, p-aminosalicylic acid, and ethionamide [17]. However, some isolates are susceptible in vitro to trimethoprimesulfamtahoxazole and linezolid [2].

To date, there is no standard treatment yet for M. simiae, but the following drugs: clarithromycin, quinolones, ethambutol, cycloserine, and ethionamide seem to be effective. Surprisingly M. simiae isolates remain sensitive to moxifloxacin even if the isolates are resistant to ciprofloxacin [2].

Regimen including moxifloxacin, clarithromycin and a third drug to which the isolate is susceptible (like trimethoprime-sulfamtahoxazole, clofazimine, streptomycin, amikacin) is the best treatment approach [2].

Aminoglycosides and clofazimine are promising therapeutic options [18].

Conclusion

M. simiae infection is uncommon and can affect immunosuppressed and immunocompetent patients as well. Its presence in respiratory specimen could represent either true infection or colonization. The clinical manifestations and radiological findings usually resemble another infectious NTM. However early diagnosis is necessary in order to implement appropriate treatment despite limited choices in such cases.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Article Usage

  • Total views: 12053
  • [From(publication date):
    March-2015 - Dec 19, 2018]
  • Breakdown by view type
  • HTML page views : 8249
  • PDF downloads : 3804
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri and Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

streamtajm

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version